Schonfeld Strategic Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-51,082	Closed	-$3.17M	–	2704
2022 Q1	$3.17M	Buy	51,082 +7,656	+18%	+$469K	0.03%	578
2021 Q4	$2.39M	Buy	+43,426	New	+$2.27M	0.02%	661
2021 Q3	–	Sell	-42,510	Closed	-$2.93M	–	2262
2021 Q2	$2.93M	Sell	42,510 -34,365	-45%	-$2.62M	0.03%	598
2021 Q1	$5.93M	Buy	76,875 +52,975	+222%	+$4.88M	0.07%	368
2020 Q4	$2.37M	Buy	23,900 +12,990	+119%	+$1.59M	0.03%	560
2020 Q3	$1.55M	Buy	+10,910	New	+$1.82M	0.03%	586
2016 Q4	–	Sell	-9,398	Closed	-$608K	–	589
2016 Q3	$608K	Buy	+9,398	New	+$530K	0.1%	247

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Schonfeld Strategic Advisors's LKFT Position: Q2 2022 in Review

Schonfeld Strategic Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2022, closing a stake of 51,082 shares — an estimated $3.17M sold.

Schonfeld Strategic Advisors first reported a position in LKFT in Q3 2016 and held it in 7 quarters. The position peaked at $5.93M in Q1 2021. 82 funds tracked by Wall St. Rank hold LKFT as of Q2 2022.

Schonfeld Strategic Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 51,082 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2022, an estimated $3.17M.
Schonfeld Strategic Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2016 and held it in 7 quarters.
Schonfeld Strategic Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.93M in Q1 2021.
82 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.